Plus Therapeutics (PSTV) announces it has received an additional 180-day extension period from the Nasdaq Listing Qualifications Department to regain compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics highlights ReSPECT-LM trial results at SITC meeting
- Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning
- Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
- Plus Therapeutics Signs Lease Agreement in Houston
- Plus Therapeutics provides update on CNSide Diagnostic platform launch